(PharmaNewsWire.Com, February 20, 2018 ) Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorders diagnosed in children around the world. DMD is often referred to as orphan or rare diseases, as it affects only a small portion of the population, approximately 1 in every 3,500 live male births. However, various treatment approaches are available now-a-days that can inhibit progression of the disease. Amongst, the most attractive are molecular based therapies, such as mutation suppression or exon skipping. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.
According to Research Cosmos new research report “Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Clinical Trial Assessment & Pipeline Analysis (By Phase, Geography, and Key Player) Outlook 2022”, the Duchenne Muscular Dystrophy Therapeutics industry can possibly turn into a multi-million dollar industry by the end of 2022, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.
The Duchenne Muscular Dystrophy Therapeutics market has very few marketed products, such as Emflaza, Translarna, and EXONDYS 51. The market is majorly in the research phase, from which most of its revenue is generated. Therefore, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the Duchenne Muscular Dystrophy market, such as phases, geographies, etc. The report also provides the sales of major marketed Duchenne Muscular Dystrophy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.
The report provides a detailed analysis of the current and future market scenario of the global Duchenne Muscular Dystrophy Therapeutics market. Research Cosmos, in its report, further covers insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Duchenne Muscular Dystrophy Therapeutics market. The report also provides insights regarding the strategies adopted by the players from 2015 to 2017 for enhancing their market share.
The segmentation of Duchenne Muscular Dystrophy Therapeutics market has been done on the basis of different therapeutic approaches and geographical regions. Primarily, the Duchenne Muscular Dystrophy Therapeutics market is dominated by mutation suppression and exon skipping approach, with several companies and academic institutions focusing on potential for each of these treatments.
Based on the geography, the market is divided into three regions, namely - North America, Europe, and Asia Pacific. There are several treatments for DMD that are approved or under review in the European Union or are expected to be under review by regulatory agencies in the near future. This is a major reason for the dominant position of Europe in the Duchenne Muscular Dystrophy market.
The later part of the report discusses some of the prominent players in the global Duchenne Muscular Dystrophy Therapeutics market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
About Us: Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
